Takeda Ventures

Startup focused on B-cell therapies launched with $52M in Series A

Massachusetts-based Be Biopharma will use the proceeds to build a team as it seeks to develop B-cell therapies for a variety of diseases.

By Joel Berg

RDMD raises $14M for rare disease real-world evidence generation

The San Francisco-based startup is one of several that have been raising money over the past couple of weeks in areas like neurology, oncology and women's health.

By Alaric DeArment

Startups, Events

What sparks the investment passions of David Shaywitz of Takeda Ventures? (Q&A)

The Takeda Ventures Senior Partner will take part in the panel discussion Trends in Oncology Investing at the MedCity CONVERGE Conference July 11-12 in Philadelphia.

By Stephanie Baum

Startups, BioPharma

In a busy field, biotech incubators are evolving

Life science incubators and accelerators are expanding and broadening their value-adds, as highlighted on Thursday by two significant announcements; one from Boston, one from Israel.

By Juliet Preston

BioPharma, Pharma

Three “hits” on biopharma market trends at mcINVEST

From money-back guarantees to a surprising source of funding, MedCity INVEST presenters and panelists discussed some of the major trends influencing the biopharma sector in 2017.

By Juliet Preston

Pharma

VCs, corporate pharma investors put $38M behind Naurex’s new treatments for depression

If there’s any truth to the notion that corporate VC-backed companies have a higher rate of overall success than those without corporate VC funding, here’s a company we should be keeping an eye on. Naurex Inc., a young pharmaceutical company focused on psychiatry and neurology, rounded up $38 million from lead investor Baxter Ventures and […]

By Deanna Pogorelc